Evidence map›Paper›PMID 31960630›Full record

ArticleBrain and behavior2020

The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD.

Cheng Li, Weizhen Liu, Xiaohui Li, Zijuan Zhang, Huaxin Qi, Shijin Liu, Ningning Yan, Ying Xing, Christian Hölscher, Zhiju Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Cheng LiDepartment of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China.
Weizhen LiuDepartment of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China.
Xiaohui LiDepartment of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China.
Zijuan ZhangDepartment of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China.
Huaxin QiDepartment of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China.
Shijin LiuDepartment of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China.
Ningning YanDepartment of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China.
Ying XingDepartment of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China.
Christian HölscherResearch and Experimental Center, Henan University of Chinese Medicine, Zhengzhou, Henan, PR China.ORCID 0000-0002-8159-3260
Zhiju WangDepartment of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China.
Zhengzhou University · CNFirst Affiliated Hospital of Henan University · CN

Funding

National Natural Science Foundation of China 81771193Scientific Research and developmentZhengzhou University
6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) is the most common progressive neurodegenerative disease for which there is no cure. Recent studies have shown a close link between type 2 diabetes and AD, which suggested that drugs for type 2 diabetes may be effective for AD. GLP-1 and GIP are incretin hormones that can ameliorate diabetes.

methodsIn the present study, we tested the novel dual GLP-1/GIP receptor agonist DA5-CH in the icv. streptozotocin (STZ)-induced insulin desensitization model of AD in rats to explore the protective effects of DA5-CH.

resultsThe results show that DA5-CH could reverse the STZ-induced working memory impairments in a Y-maze tests, and spatial memory impairments in the water maze task, and decrease the levels of phosphorylated tau

conclusionTherefore, our results demonstrate that DA5-CH has neuroprotective effects in the STZ-induced animal model and that DA5-CH has potential to treat neurodegenerative disorders such as AD.

Indexed as

Alzheimer DiseaseAnimalsDisease Models, AnimalGlucagon-Like Peptide 1HippocampusMaleMaze LearningMemory, Short-TermNeuroprotective AgentsPeptidesPhosphorylationRatsRats, Sprague-DawleySignal TransductionStreptozocintau ProteinsDA5-CH peptideGlucagon-Like Peptide 1Neuroprotective AgentsPeptidesStreptozocintau ProteinsAlzheimer's diseaseapoptosisCREBGLP-1/GIP dual agonistgrowth factorstreptozotocintheta band frequency

Identifiers

PMID31960630
PMCPMC7066337
OpenAlexW3001146304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.